Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zivo BioscienceZIVO 8 Receivables Turnover is 1.94 as of Sep. 2025. GuruFocus rates ZIVO with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Zivo Bioscience ranks better than 77.17% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zivo Bioscience's Revenue for the
three
months ended in Sep. 2025 was $0.07 Mil. Zivo Bioscience's average Accounts Receivable for the
three
months ended in Sep. 2025 was $0.03 Mil.
Hence, Zivo Bioscience's Receivables Turnover for the
three
months ended in Sep. 2025 was 1.94.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zivo Bioscience Receivables Turnover Related Terms
Zivo Bioscience Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Zivo Bioscience's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZIVO vs ATOS, QNCX, AEON: Receivables Turnover Comparison
For the Biotechnology subindustry, Zivo Bioscience's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zivo Bioscience Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zivo Bioscience's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience (ZIVO) has a Receivables Turnover of 1.94 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zivo Bioscience and its competitors. According to the industry distribution chart, Zivo Bioscience ranks #192 out of 841 companies in the Biotechnology industry, placing it in the top 22.8%.
Is Zivo Bioscience's Receivables Turnover too high?
Zivo Bioscience's current Receivables Turnover is 1.94. The Biotechnology industry median Receivables Turnover is 5.27. Zivo Bioscience's value of 1.94 is 63.2% below this industry median. Based on the distribution chart, Zivo Bioscience ranks #192 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zivo Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zivo Bioscience's Receivables Turnover compare to ATOS and QNCX?
According to the Biotechnology industry distribution chart, Zivo Bioscience ranks #192 out of 841 companies for Receivables Turnover. This places Zivo Bioscience in the top 23% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Zivo Bioscience's value of 1.94 is 63.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zivo Bioscience's current Receivables Turnover of 1.94 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zivo Bioscience and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zivo Bioscience's current Receivables Turnover is 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zivo Bioscience stock overvalued right now?
Zivo Bioscience (ZIVO) has a current Receivables Turnover of 1.94. The current Receivables Turnover is 1.94 and 63.2% below the Biotechnology industry median of 5.27. Zivo Bioscience's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zivo Bioscience (ZIVO), the current Receivables Turnover is 1.94 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zivo Bioscience Inc operates in one reportable segment microalgae technology. The segment is research and development operating in both the therapeutic and nutritional sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's applications are ANIMAL APPLICATIONS, HUMAN APPLICATIONS.
8GF Score
Get the complete analysis for ZIVO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZIVO has been successfully added to your 
